Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 240

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 240
---
 term, which may be renewed for subsequent three-month terms upon 30 days’ notice. Dr. Itri will continue to vest in her outstanding Company equity awards in accordance with their terms for the duration of time
that she continues to serve as a consultant.

Equity Awards

On March 1, 2024, we granted awards of restricted stock units and stock options under our 2021 Plan to each of our named executive officers other than Dr.
Desai.

With respect to such restricted stock unit awards, we granted restricted stock units covering 65,000 shares to Dr. Lennon, restricted stock
units covering 27,000 shares to Mr. Giacobello, restricted stock units covering

- 166 -

20,000 shares to Mr. Ball, and restricted stock units covering 30,000 shares to Dr. Itri. With respect to such awards granted to our named executive officers, other than Dr. Desai, 25% of such restricted stock units will vest on each anniversary of the grant date, subject to continued service to us through each applicable vesting date. With respect to such awards of stock options, we granted options to purchase 160,768 shares to Dr. Lennon, options to purchase 193,263 shares to Mr. Giacobello, options to purchase 105,809 shares to Mr. Ball, and options to purchase 136,813 shares to Dr. Itri. Options to purchase 30,768 shares granted to Dr. Lennon, options to purchase 138,263 shares granted to Mr. Giacobello, options to purchase 65,809 shares granted to Mr. Ball, and options to purchase 76,813 shares granted to Dr. Itri were granted in respect of amounts payable to such named executive officers under our 2023 bonus plan and were fully vested at grant. The remainder of such options granted to our named executive officers in 2024 are scheduled to vest as to 25% of the share subject thereto on the first anniversary of the grant date, and 1/48 thof the shares subject thereto each month thereafter, subject to continued service to us through each applicable vesting date. Quantification of Potential Payments to Certain Named Executive Officers in Connection with the Divestiture In accordance with Item 402(t) of Regulation S-K,the table below sets forth the compensation that is based on or otherwise relates to the Divestiture that will or may become payable to certain executive officers in connection with the Divestiture. The table below assumes that